NASDAQ:CAMP - Nasdaq - US13463J1016 - Currency: USD
4.81
-0.02 (-0.41%)
The current stock price of CAMP is 4.81 USD. In the past month the price decreased by -11.58%. In the past year, price decreased by -20.93%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
CAMP4 Therapeutics Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2024-10-11. CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. The company is leveraging its RAP Platform to advance a pipeline of programs initially focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
CAMP4 THERAPEUTICS CORP
One Kendall Square, Bldg 1400 West 3rd Floor
Cambridge MASSACHUSETTS 92618 US
CEO: Jeffery Gardner
Employees: 58
Company Website: https://www.camp4tx.com/
Phone: 16176518867
The current stock price of CAMP is 4.81 USD. The price decreased by -0.41% in the last trading session.
The exchange symbol of CAMP4 THERAPEUTICS CORP is CAMP and it is listed on the Nasdaq exchange.
CAMP stock is listed on the Nasdaq exchange.
10 analysts have analysed CAMP and the average price target is 19.38 USD. This implies a price increase of 302.91% is expected in the next year compared to the current price of 4.81. Check the CAMP4 THERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CAMP4 THERAPEUTICS CORP (CAMP) has a market capitalization of 96.97M USD. This makes CAMP a Micro Cap stock.
CAMP4 THERAPEUTICS CORP (CAMP) currently has 58 employees.
CAMP4 THERAPEUTICS CORP (CAMP) has a support level at 4.78 and a resistance level at 5.11. Check the full technical report for a detailed analysis of CAMP support and resistance levels.
The Revenue of CAMP4 THERAPEUTICS CORP (CAMP) is expected to decline by -92.93% in the next year. Check the estimates tab for more information on the CAMP EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CAMP does not pay a dividend.
CAMP4 THERAPEUTICS CORP (CAMP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-22.81).
The outstanding short interest for CAMP4 THERAPEUTICS CORP (CAMP) is 2.35% of its float. Check the ownership tab for more information on the CAMP short interest.
ChartMill assigns a fundamental rating of 1 / 10 to CAMP. CAMP has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months CAMP reported a non-GAAP Earnings per Share(EPS) of -22.81. The EPS decreased by -17446.15% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -36.04% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 86% to CAMP. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -591.99% and a revenue growth -92.93% for CAMP